68Ga-DOTATATE PET/CT Detection of Hypertrophic Osteoarthropathy in a Pediatric Patient With Neuroblastoma Following Anti-GD2 Immunotherapy.

Clin Nucl MedOct 8, 2026 (epub)

Siqi Li, Xiaoya Wang, Keyu Zhang et al.

✦ AI-curated · Sources linked

Case in brief

A 5-year-old boy with high-risk neuroblastoma underwent 68Ga-DOTATATE PET/CT to assess response after anti-GD2 immunotherapy. Imaging showed symmetric increased uptake in both femora and tibiae, accompanied by periostosis. 18F-MFBG PET/CT showed no abnormal uptake, and no metastases were identified. The findings were diagnosed as hypertrophic osteoarthropathy, reported as a rare complication following anti-GD2 therapy.

What made this case unusual

The symmetric long-bone uptake and periostosis on 68Ga-DOTATATE PET/CT represented hypertrophic osteoarthropathy rather than metastatic disease; 18F-MFBG PET/CT showed no abnormal uptake.

Diagnostic / clinical pearl

In a child with neuroblastoma after anti-GD2 immunotherapy, symmetric long-bone uptake with periostosis on 68Ga-DOTATATE PET/CT may indicate hypertrophic osteoarthropathy, particularly when metastatic disease is not found.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.